SPDW vs XBI
SPDR Portfolio Developed World ex-US ETF vs SPDR S&P Biotech ETF
- • SPDW has the lower expense ratio at 0.03% vs 0.35% for XBI.
- • SPDW pays a higher dividend yield (3.06%).
Side-by-side metrics
| Metric | SPDW | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.03% | 0.35% |
Dividend yield Trailing 12-month yield. | 3.06% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $40.99B | $10.92B |
YTD return | 13.40% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.04 | 1.01 |
P/E ratio | 16.18 | — |
Last price | $49.73 | $156.41 |
Inception | — | — |
Issuer | State Street | State Street |
SPDW top holdings
| 000660.KQ | SK hynix Inc | 1.88% |
| ASML.AS | ASML Holding NV | 1.85% |
| ROP.SW | Roche Holding AG Ordinary Shares new | 1.04% |
| SHEL.L | Shell PLC | 0.95% |
| NOVN.SW | Novartis AG Registered Shares | 0.91% |
| HSBA.L | HSBC Holdings PLC | 0.89% |
| AZN.L | AstraZeneca PLC | 0.88% |
| RY | Royal Bank of Canada | 0.86% |
| NESN.SW | Nestle SA | 0.81% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SPDW
SPDW (SPDR Portfolio Developed World ex-US ETF) is Developed-market stocks outside the US. Managed by State Street, the fund carries $41.0B in assets under management, an expense ratio of 0.03%, a dividend yield of 3.06%. Its largest holding is SK hynix Inc (000660.KQ), which represents 1.9% of the portfolio. Real Estate is the fund's largest sector exposure at 2.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.